Welcome to the e-CCO Library Archive!
P471
Safety analysis of multimatrix mesalazine amongst patients with ulcerative colitis or recurrent diverticulitis ≥ 55 years of age
G. Lichtenstein1, K. Barrett2, D. Stefani-Hunyady3, F. Cataldi*4, J. Raskin5
1University of Pennsylvania Healthy System, Inflammatory Bowel Disease Centre, Philadelphia, Pennsylvania, United States, 2Shire, Basingstoke, United Kingdom, 3Shire, Lexington, Massachusetts, United States, 4Shire, Gastroenterology, Lexington, Massachusetts, United States, 5University of Miami Health System, Gastroenterology and Internal Medicine, Miami, Florida, United States
P472
Faecal calprotectin as a biomarker of early mucosal healing in patients with ulcerative colitis naïve to adalimumab treatment
C. Muñoz Villafranca*1, A. Perez de Arenaza2, L. Gómez3, R. Higuera4, A. Munagorri5, M. A. Ogueta6, S. Ibañez7, J. Ortiz de Zárate8, O. Merino3, C. Rodriguez9, O. Nante9, P. Arreba10, P. Ramirez de la Piscina11, I. Rodríguez12, A. Bernal13, J. A. Arévalo13, J. L. Cabriada13
1Hospital Universitario de Basurto, Aparato Digestivo, Bilbao, Spain, 2Hospital Universitario de Basurto, Bilbao, Spain, 3Hospital Universitario de Cruces, Gastroenterology, Baracaldo, Spain, 4Hospital San Eloy, Gastroenterology, Baracaldo, Spain, 5Hospital Donostia, Gastroenterology, Donosti, Spain, 6Hospital de Santiago, Gastroenterology, Vitoria, Spain, 7Hospital Universitario de Cruces, Gastroenterology, Baracaldo, Spain, 8Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain, 9Hospital de Navarra, Gastroenterology, Pamplona, Spain, 10Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain, 11Hospital de Txagorritxu, Gastroenterology, Vitoria, Spain, 12Hospital de Galdakao, Galdakao, Spain, 13Hospital de Galdácano, Gastroenterology, Galdácano, Spain
P473
Clinical and biochemical factors that influence response in inflammatory disease patients receiving tacrolimus
I. Rodríguez - Lago*1, 2, O. Merino2, 3, O. Nantes2, 4, C. Muñoz2, 5, U. Aguirre6, J. L. Cabriada1, 2
1Galdakao Hospital, Gastroenterology, Galdakao, Spain, 2IBD Study Group of the Basque – Navarre Society of Gastrointestinal Diseases, Pais Vasco - Navarra, Spain, 3Cruces University Hospital, Gastroenterology, Bilbao, Spain, 4Complejo Hospitalario de Navarra, Gastroenterology Department, Pamplona, Spain, 5Basurto University Hospital, Gastroenterology, Bilbao, Spain, 6Galdakao Hospital, Research Unit, Galdakao, Spain
P474
Assessing the position of systemic tacrolimus in the treatment of inflammatory bowel disease: systematic review and meta-analysis
M. Lie*, J. Kreijne, B. Hansen, J. van der Woude
Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands
P475
Gastroenterological and reumatological chronic patients: are there differences in individual welfare and quality of life?—a cross-observational study
A. Stefani, M. G. Vettorato*, G. Lorenzon, T. Marcon, F. Simonetti, A. Rigo, E. V. Savarino, E. De Marchi, R. D’Incà, G. C. Sturniolo
University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy, Padua, Italy
P476
Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with quiescent inflammatory bowel disease: a double-blind, placebo-controlled, randomised, cross-over re-challenge trial
S. Cox*1, A. Prince1, 2, C. Myers1, 3, P. M. Irving1, 4, J. O. Lindsay5, M. C. Lomer1, 4, K. Whelan1
1King’s College London, School of Medicine, Diabetes and Nutritional Sciences Division, London, United Kingdom, 2King’s College Hospital NHS Foundation Trust, Nutrition and Dietetics, London, United Kingdom, 3The Royal Surrey County Hospital NHS Trust, Nutrition and Dietetics, Guildford, United Kingdom, 4Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom, 5Barts Health NHS Trust, Gastroenterology, London, United Kingdom
P477
Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn’s disease: a tertiary centre real-life experience
M. Allocca*1, G. Fiorino1, C. Bonifacio2, A. Spinelli3, A. Repici4, A. Malesci5, 6, L. Balzarini2, S. Danese1, 7
1Humanitas Research Hospital, IBD Centre, Gastroenterology, Rozzano, Milan, Italy, 2Humanitas Research Hospital, Radiology, Rozzano, Milan, Italy, 3Humanitas Research Hospital, IBD Surgery, Colo-rectal Surgery, Rozzano, Milan, Italy, 4Humanitas Research Hospital, Endoscopy Unit, Gastroenterology, Rozzano, Milan, Italy, 5Humanitas Research Hospital, Gastroenterology, Rozzano, Milan, Italy, 6University of Milan, Translational Medicine, Milan, Italy, 7Humanitas University, Biomedical Sciences, Rozzano, Milan, Italy
P478
How often high-dose budesonide is necessary for maintenance treatment of collagenous colitis? Efficacy of azathioprine to maintain budesonide-free clinical remission
F. Fernández-Bañares*1, M. Piqueras2, D. Guagnozzi3, V. Robles4, A. Ruiz-Cerulla5, M. J. Casanova6, J. P. Gisbert6, D. Busquets7, A. Lucendo8, Y. Arguedas9, L. Fernández10
1Hospital Universitari Mutua Terrassa, Gastroenterology, CIBERehd, Terrassa, Spain, 2Consorci Sanitari Terrassa, Gastroenterology, Terrassa, Spain, 3Hospital Vall d’Hebron, Gastroenterology, Barcelona, Spain, 4Hospital Vall d’Hebron, Department of Gastroenterology, Barcelona, Spain, 5Hospital de Bellvitge, Gastroenterology, L’Hospitalet de Llobregat, Spain, 6Hospital Universitario de La Princesa, Gastroenterology, CIBERehd, Madrid, Spain, 7Hospital Universitari Dr Josep Trueta, Department of Gastroenterology, Girona, Spain, 8Hospital General De Tomelloso, Department of Gastroenterology, Tomelloso, Spain, 9Hospital San Jorge, Gastroenterology, Huesca, Spain, 10Hospital University Clinic Valladolid, Department of Gastroenterology, Valladolid, Spain
P479
Hepcidin and the risk of malnutrition in inflammatory bowel disease
R. Dudkowiak*, K. Neubauer, E. Poniewierka
Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland
P480
Goals of treatment: preferences of inflammatory bowel disease patients
F. Casellas*1, 2, C. Herrera de Guise1, V. Robles1, E. Navarro1, N. Borruel1
1Hospital Universitari Vall d’Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain, 2Hospital Universitari Vall d’Hebron, Barcelona, Spain
P481
Effect of anti-TNFα therapy with daily physical activity in patients with Crohn’s disease
F. A. Lucca, C. Malaguti, A. L. Cabalzar, L. A. Chebli, T. C. R. Ribeiro*, P. D. Gaburri, J. M. F. Chebli
Universidade Federal de Juiz de Fora, Gastroenterology, Juiz de Fora, Brazil
P482
Different characteristics of inflammatory bowel disease patients between tertiary referral centres and secondary hospitals
K. H. Song*1, Y. J. Lee2, K. O. Kim3, H. S. Lee4, E. S. Kim2, J. I. Koo1, J. S. Jeong1, W. S. Seo1
1Goo Hospital, General Surgery, Daegu, South Korea, 2Keimyung University School of Medicine, Internal Medicine, Daegu, South Korea, 3Yeungnam University College of Medicine, Internal Medicine, Daegu, South Korea, 4Kyungpook National University School of Medicine, Department of Internal Medicine, Daegu, South Korea
P483
Differences in biologic therapy utilisation amongst early and late-onset inflammatory bowel disease
S. Raimundo Fernandes*, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, L. Correia, J. Velosa
Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal
P484
Access to biologics and biosimilars across 11 European Union countries
P. Lakatos*1, E. Domenech2, H. Kellner3, J. Marsal4, H. Fowler5, C. Agboton5, N. Georgitseas6, M. Cassese7, S. Anwar6, A. Venugopal7, P. Audhya5
1Semmelweis University, Budapest, Hungary, 2Hospital Universitari Germans Trias i Pujol., Badalona, Spain, 3Facharzt für Innere Medizin, Munich, Germany, 4Lund University, Lund, Sweden, 5Hospira, Warwickshire, United Kingdom, 6Navigant, London, United Kingdom, 7Navigant, New York, New York, United States
P485
The combined of mesenchymal stem cells and infliximab reduces the recurrence rate of Crohn’s disease
O. Knyazev1, N. Fadeeva*2, A. Kagramanova1, P. Shcherbakov3, I. Ruchkina1, A. Parfenov1, A. Konoplyannikov4
1Moscow Clinical Research Centre, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 2Moscow Clinical Research Centre, Department of Inflammatory bowel disease, Moscow, Russian Federation, 3Central Research Institute of Gastroenterology, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 4Medical Radiological Scientific Centre, Department of Stem Cells Therapy, Obninsk, Russian Federation
P486
Intrapatient variability in adalimumab drug levels within and across cycles in Crohn’s disease
M. Ward*1, 2, L. Beswick2, P. Thwaites1, J. Hogg1, G. Rosella3, J. Reynolds4, D. Van Langenberg2, P. Gibson1, 3, M. Sparrow1, 3
1Alfred Hospital, Gastroenterology, Melbourne, Australia, 2Eastern Health, Gastroenterology, Melbourne, Australia, 3Monash University, Faculty of Medicine, Nursing and Health Sciences, Melbourne, Australia, 4Monash University, Biostatistics, Faculty of Medicine, Nursing and Health Sciences, Melbourne, Australia
P487
The effect of a coordinated care programme for inflammatory bowel diseases on health care utilisation
W. K. van Deen*1, M. Skup2, A. Centeno1, N. Duran1, P. Lacey1, D. Jatulis3, E. Esrailian1, M. G. van Oijen4, D.W. Hommes1
1UCLA Centre for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, California, United States, 2AbbVie, US Immunology, North Chicago, Illinois, United States, 3Anthem Blue Cross, California, Woodland Hills, California, United States, 4Academic Medical Centre, Amsterdam, Department of Medical Oncology, Amsterdam, Netherlands
P488
IBS-type symptoms in patients with quiescent inflammatory bowel disease are unrelated to ongoing inflammation
D. Hoekman*1, J. Zeevenhooven2, G. D’Haens3, M. Benninga1
1Academic Medical Centre (AMC), Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 2Academic Medical Centre (AMC), Department of Paediatric Gastroenterology and Nutrition, Amsterdam, Netherlands, 3Academic Medical Centre (AMC), Department of Gastroenterology,
P489
Predicting mucosal state with faecal calprotectin in children with Crohn’s disease.
M. Meglicka*1, M. Szczepanski2, M. Dadalski2, J. Kierkus2
1The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, 2The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland
P490
Clinicians’ adherence to European Crohn’s and Colitis Organisation guidelines in the clinical care of adults with inflammatory bowel disease
B. Jackson*, D. Con, P. De Cruz
Austin Health, Gastroenterology, Melbourne, Australia